April 23, 2020 / 10:12 AM / a month ago

BRIEF-Theravance Biopharma Announces First Subject Dosed In Phase 1 Study Of Td-0903, In Development For Treatment Of Hospitalized Patients With Acute Lung Injury Caused By COVID-19

April 23 (Reuters) - Theravance Biopharma Inc:

* THERAVANCE BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 STUDY OF TD-0903, IN DEVELOPMENT FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY CAUSED BY COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below